355 related articles for article (PubMed ID: 31713639)
1. Dehydroepiandrosterone on metabolism and the cardiovascular system in the postmenopausal period.
Teixeira CJ; Veras K; de Oliveira Carvalho CR
J Mol Med (Berl); 2020 Jan; 98(1):39-57. PubMed ID: 31713639
[TBL] [Abstract][Full Text] [Related]
2. Dehydroepiandrosterone supplementation is not beneficial in the late postmenopausal period in diet-induced obese rats.
Teixeira CJ; Ribeiro LM; Veras K; da Cunha Araujo LC; Curi R; de Oliveira Carvalho CR
Life Sci; 2018 Jun; 202():110-116. PubMed ID: 29601891
[TBL] [Abstract][Full Text] [Related]
3. Six-month oral dehydroepiandrosterone supplementation in early and late postmenopause.
Stomati M; Monteleone P; Casarosa E; Quirici B; Puccetti S; Bernardi F; Genazzani AD; Rovati L; Luisi M; Genazzani AR
Gynecol Endocrinol; 2000 Oct; 14(5):342-63. PubMed ID: 11109974
[TBL] [Abstract][Full Text] [Related]
4. DHEA therapy in postmenopausal women: the need to move forward beyond the lack of evidence.
Genazzani AR; Pluchino N
Climacteric; 2010 Aug; 13(4):314-6. PubMed ID: 20540592
[TBL] [Abstract][Full Text] [Related]
5. DHEA for postmenopausal women: a review of the evidence.
Panjari M; Davis SR
Maturitas; 2010 Jun; 66(2):172-9. PubMed ID: 20089375
[TBL] [Abstract][Full Text] [Related]
6. DHEA, important source of sex steroids in men and even more in women.
Labrie F
Prog Brain Res; 2010; 182():97-148. PubMed ID: 20541662
[TBL] [Abstract][Full Text] [Related]
7. Oral dehydroepiandrosterone supplementation modulates spontaneous and growth hormone-releasing hormone-induced growth hormone and insulin-like growth factor-1 secretion in early and late postmenopausal women.
Genazzani AD; Stomati M; Strucchi C; Puccetti S; Luisi S; Genazzani AR
Fertil Steril; 2001 Aug; 76(2):241-8. PubMed ID: 11476767
[TBL] [Abstract][Full Text] [Related]
8. Dehydroepiandrosterone, obesity and cardiovascular disease risk: a review of human studies.
Tchernof A; Labrie F
Eur J Endocrinol; 2004 Jul; 151(1):1-14. PubMed ID: 15248817
[TBL] [Abstract][Full Text] [Related]
9. Long-term low-dose dehydroepiandrosterone oral supplementation in early and late postmenopausal women modulates endocrine parameters and synthesis of neuroactive steroids.
Genazzani AD; Stomati M; Bernardi F; Pieri M; Rovati L; Genazzani AR
Fertil Steril; 2003 Dec; 80(6):1495-501. PubMed ID: 14667889
[TBL] [Abstract][Full Text] [Related]
10. Physiological importance of dehydroepiandrosterone.
Ebeling P; Koivisto VA
Lancet; 1994 Jun; 343(8911):1479-81. PubMed ID: 7911183
[TBL] [Abstract][Full Text] [Related]
11. Metabolic effects of 12-month percutaneous dehydroepiandrosterone replacement therapy in postmenopausal women.
Diamond P; Cusan L; Gomez JL; Bélanger A; Labrie F
J Endocrinol; 1996 Sep; 150 Suppl():S43-50. PubMed ID: 8943786
[TBL] [Abstract][Full Text] [Related]
12. Metabolic effects of dehydroepiandrosterone replacement therapy in postmenopausal women.
Lasco A; Frisina N; Morabito N; Gaudio A; Morini E; Trifiletti A; Basile G; Nicita-Mauro V; Cucinotta D
Eur J Endocrinol; 2001 Oct; 145(4):457-61. PubMed ID: 11581005
[TBL] [Abstract][Full Text] [Related]
13. Dehydroepiandrosterone (DHEA) and DHEA-sulfate (DS) as therapeutic options in menopause.
Katz S; Morales AJ
Semin Reprod Endocrinol; 1998; 16(2):161-70. PubMed ID: 9711682
[TBL] [Abstract][Full Text] [Related]
14. [Study on relationship between endogenous androgens and insulin resistance at the different stages of postmenopause].
Cao YK; Zhang SF; Zou SE; Xia X; Xu LN
Zhonghua Fu Chan Ke Za Zhi; 2013 Oct; 48(10):740-4. PubMed ID: 24406129
[TBL] [Abstract][Full Text] [Related]
15. The effects of oral dehydroepiandrosterone on endocrine-metabolic parameters in postmenopausal women.
Mortola JF; Yen SS
J Clin Endocrinol Metab; 1990 Sep; 71(3):696-704. PubMed ID: 2144295
[TBL] [Abstract][Full Text] [Related]
16. Supplementation of dehydroepiandrosterone (DHEA) in pre- and postmenopausal women - position statement of expert panel of Polish Menopause and Andropause Society.
Rabijewski M; Papierska L; Binkowska M; Maksym R; Jankowska K; Skrzypulec-Plinta W; Zgliczynski W
Ginekol Pol; 2020; 91(9):554-562. PubMed ID: 33030737
[TBL] [Abstract][Full Text] [Related]
17. Clinical review: DHEA replacement for postmenopausal women.
Davis SR; Panjari M; Stanczyk FZ
J Clin Endocrinol Metab; 2011 Jun; 96(6):1642-53. PubMed ID: 21411558
[TBL] [Abstract][Full Text] [Related]
18. Dehydroepiandrosterone Research: Past, Current, and Future.
Klinge CM; Clark BJ; Prough RA
Vitam Horm; 2018; 108():1-28. PubMed ID: 30029723
[TBL] [Abstract][Full Text] [Related]
19. Dehydroepiandrosterone therapy as female androgen replacement.
Saltzman E; Guay A
Semin Reprod Med; 2006 Apr; 24(2):97-105. PubMed ID: 16633983
[TBL] [Abstract][Full Text] [Related]
20. Differential effect of oral dehydroepiandrosterone-sulphate on metabolic syndrome features in pre- and postmenopausal obese women.
Gómez-Santos C; Hernández-Morante JJ; Tébar FJ; Granero E; Garaulet M
Clin Endocrinol (Oxf); 2012 Oct; 77(4):548-54. PubMed ID: 22136516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
